Safety and tolerability of extended-release niacin with laropiprant

Bibliography

• Ridker PM, Genest J, Boekholdt SM, HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010;11:333-9
   Google Scholar
• Panel AP. Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment. Diab Vasc Dis Res 2006;3:S1-S12
   PubMedGoogle Scholar
• Durrington P. Hyperlipidaemia Diagnosis and Management. 3rd edition. Hodder Arnold; London: 2007
   Google Scholar
• Castelli WP, Garrison RJ, Wilson PW, Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8
   PubMed Web of Science ®Google Scholar
• Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8
   PubMed Web of Science ®Google Scholar
• Shah PK, Kaul S, Nilsson J, Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001;104:2376-83
   PubMed Web of Science ®Google Scholar
• Soran H, Younis NN, Charlton-Menys V, Variation in paraoxonase-1 activity and atherosclerosis. Curr Opin Lipidol 2009;20:265-74
   PubMed Web of Science ®Google Scholar
• Navab M, Reddy ST, Van Lenten BJ, HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011;8:222-32
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ, Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
   PubMed Web of Science ®Google Scholar
• Lee JM, Robson MD, Yu LM, Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-94
   PubMed Web of Science ®Google Scholar
• Carlson LA, Oro L, Ostman J. Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. Acta Med Scand 1968;183:457-65
   PubMedGoogle Scholar
• Parsons WB Jr, AchorRW, BergeKG, . Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations. Proc Staff Meet Mayo Clin 1956;31:377-90
   PubMed Web of Science ®Google Scholar
• Parsons WB Jr, Flinn JH. Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid. AMA Arch Intern Med 1959;103:783-90
   PubMedGoogle Scholar
• NIH stops clinical trial on combination cholesterol treatment: lack of efficacy in reducing cardiovascular events prompts decision. National Institute of Health News 2011. Available from: http://www.nih.gov/news/health/may2011/nhlbi-26.htm
   Google Scholar
• Whelan AM, Price SO, Fowler SF, The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 1992;34:165-8
   PubMed Web of Science ®Google Scholar
• Gleim G. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol 2009;16:90-7
   Google Scholar
• Shah S, Ceska R, Gil-Extremera B, Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2010;64:727-38
   PubMed Web of Science ®Google Scholar
• Maccubbin D, Bays HE, Olsson AG, Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-70
   PubMed Web of Science ®Google Scholar
• Karpe F, Frayn KN. The nicotinic acid receptor–a new mechanism for an old drug. Lancet 2004;363:1892-4
   PubMed Web of Science ®Google Scholar
• Ganji SH, Tavintharan S, Zhu D, Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004;45:1835-45
   PubMed Web of Science ®Google Scholar
• Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-8
   PubMed Web of Science ®Google Scholar
• Acton S, Rigotti A, Landschulz KT, Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996;271:518-20
   PubMed Web of Science ®Google Scholar
• Martinez LO, Jacquet S, Esteve JP, Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003;421:75-9
   PubMed Web of Science ®Google Scholar
• Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004;67:411-19
   PubMed Web of Science ®Google Scholar
• van der Hoorn JW, de Haan W, Berbee JF, Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008;28:2016-22
   PubMed Web of Science ®Google Scholar
• Ganji SH. Niacin inhibits LDL oxidation and redox-sensitive VCAM-1 and MCP-1 expression in human aortic endothelial cells. Arterioscler Thromb Vasc Biol 2004;24:125
   Web of Science ®Google Scholar
• Ganji SH, Qin S, Zhang L, Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009;202:68-75
   PubMed Web of Science ®Google Scholar
• Mrochek JE, Jolley RL, Young DS, Metabolic response of humans to ingestion of nicotinic acid and nicotinamide. Clin Chem 1976;22:1821-7
   PubMed Web of Science ®Google Scholar
• Cayen MN. Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man. Pharmacol Ther 1985;29:157-204
   PubMed Web of Science ®Google Scholar
• Miller ON, Hamilton JG, Goldsmith GA. Investigation of the mechanism of action of nicotinic acid on serum lipid levels in man. Am J Clin Nutr 1960;8:480-90
   PubMed Web of Science ®Google Scholar
• Knopp RH, Ginsberg J, Albers JJ, Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642-50
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 2004;62:229-34
   PubMed Web of Science ®Google Scholar
• Illingworth DR, Stein EA, Mitchel YB, Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994;154:1586-95
   PubMed Web of Science ®Google Scholar
• Mills E, Prousky J, Raskin G, The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. BMC Clin Pharmacol 2003;3:4-12
   PubMedGoogle Scholar
• Kamal-Bahl SJ, Burke T, Watson D, Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007;99:530-4
   PubMed Web of Science ®Google Scholar
• Kamal-Bahl SJ, Burke TA, Watson DJ, Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Curr Med Res Opin 2008;24:1817-21
   PubMed Web of Science ®Google Scholar
• Benyo Z, Gille A, Bennett CL, Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol 2006;70:1844-9
   PubMed Web of Science ®Google Scholar
• Benyo Z, Gille A, Kero J, GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005;115:3634-40
   PubMed Web of Science ®Google Scholar
• Maciejewski-Lenoir D, Richman JG, Hakak Y, Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 2006;126:2637-46
   PubMed Web of Science ®Google Scholar
• Sturino CF, O'Neill G, Lachance N, Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 2007;50:794-806
   PubMed Web of Science ®Google Scholar
• MSD. Summary of product characteristics TREDAPTIVE 1000 mg/20 mg modified release tablets. 2011. Available from: http://www.medicines.org.uk/EMC/medicine/22227/SPC/TREDAPTIVE+1000+mg+20+mg+modified+release+tablets/
   Google Scholar
• Dallob A, Luo WL, Luk JM, The effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets 2011;22:495-503
   PubMed Web of Science ®Google Scholar
• Lai E, Schwartz JI, Dallob A., Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets 2010;21:191-8
   PubMed Web of Science ®Google Scholar
• Bays HE, Dujovne CA, McGovern ME, Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003;91:667-72
   PubMed Web of Science ®Google Scholar
• Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 2003;6:179-88
   PubMedGoogle Scholar
• Managing Dyslipidemias in Patients With Chronic Kidney Disease - Guidelines. 2003, The National Kidney Foundation KDOQI
   Google Scholar
• Increased myopathy with combination use of ER niacin/laropiprant (Tredaptive®) and simvastatin 40 mg in Chinese patients. Results from interim analysis of HPS2-THRIVE study. Safety alerts 2010. Available from: http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/safety_information/product_safety_alerts/safety_alerts_2010/increased_myopathy.html
   Google Scholar
• Tato F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998;81:805-7
   PubMed Web of Science ®Google Scholar
• Capuzzi DM, Guyton JR, Morgan JM, Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82:74U-81U; discussion 5U-6U
   PubMed Web of Science ®Google Scholar
• Vaccari CS, Hammoud RA, Nagamia SH, Revisiting niacin: reviewing the evidence. J Clin Lipidol 2007;1:248-55
   PubMed Web of Science ®Google Scholar
• Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004;5:1385-98
   PubMed Web of Science ®Google Scholar
• Henkin Y, Oberman A, Hurst DC, Niacin revisited: clinical observations on an important but underutilized drug. Am J Med 1991;91:239-46
   PubMed Web of Science ®Google Scholar
• Schwartz ML. Severe reversible hyperglycemia as a consequence of niacin therapy. Arch Intern Med 1993;153:2050-2
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, McGovern ME, Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-76
   PubMed Web of Science ®Google Scholar
• Maccubbin D, Koren MJ, Davidson M, Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009;104:74-81
   PubMed Web of Science ®Google Scholar
• Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007;99:22C-31C
   PubMed Web of Science ®Google Scholar
• Paolini JF, Mitchel YB, Reyes R, Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625-30
   PubMed Web of Science ®Google Scholar
• Lai E, Wenning LA, Crumley TM, Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008;83:840-7
   PubMed Web of Science ®Google Scholar
• McKenney J, Bays H, Koren M, Safety of extended-release niacin/laropiprant in patients with dyslipidemia. J Clin Lipidol 2010;4:105-12
   PubMed Web of Science ®Google Scholar
• Lauring B, Dishy V, Luo WL, Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. J Clin Pharmacol 2009;49:1426-35
   PubMed Web of Science ®Google Scholar
• Norquist JM, Watson DJ, Yu Q, Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin 2007;23:1549-60
   PubMed Web of Science ®Google Scholar
• Maclean A. Efficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitus. Br J Cardiol 2011;18:37-45
   Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97
   PubMed Web of Science ®Google Scholar